FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1506567021> ?p ?o ?g. }

• W1506567021 endingPage "250" @default.
• W1506567021 startingPage "248" @default.
• W1506567021 abstract "Ambermoon et al. 1 review the phenomenon of levodopa abuse in Parkinson's disease (PD), and conclude that it ought to be labeled an addiction. The case is strong: affected patients display both behavioral and neurochemical features reminiscent of addiction to stimulant drugs. They take excessive amounts of levodopa, beyond the amount needed for relief of motor symptoms, even when this causes unpleasant side effects. Attempts by their physician to reduce dosage are met with anxiety, compulsive drug-seeking, hoarding and attempts to obtain multiple prescriptions. Neurochemically, levodopa is converted to dopamine and, like almost all drugs of abuse, ingestion leads to relatively rapid increases in synaptic dopamine. There is some evidence that levodopa-abusing patients display sensitization 2, i.e. a progressive increase in efficacy with repeated use. Note, however, that sensitization should not be considered a sine qua non of addiction. Indeed, sensitization to the clinical antiparkinsonian effects of levodopa occurs normally after initiation of treatment 3. The clinical features of levodopa abuse have implications for addiction in general. For example, the risk factors for its development in PD are also risk factors for addiction in the general population. These include the personality trait of novelty seeking, a family history of addiction or mood disorder and younger age, features that suggest a pre-existing vulnerability. Certain PD patients develop a slightly different medication-induced behavioral syndrome that manifests as pathological gambling, hypersexuality or compulsive shopping 4, 5. These disorders are also reminiscent of drug addiction, and indeed there is a move to re-classify them as behavioral addictions rather than ‘impulse control disorders’6. As in drug addiction, affected individuals engage in compulsive uncontrolled behaviors that persist in the face of adverse effects. There is a key difference, however, between behavioral addictions and dopaminergic medication abuse in PD: the former appear to be caused almost exclusively by dopamine agonists 7, 8 such as pramipexole and ropinirole, while medication abuse is essentially only described in patients receiving levodopa 9. What is the cause of this dichotomy? A clue resides in the mode of action of the two types of drugs, and the dichotomy may tell us something about the neurochemistry of addiction and reward. Levodopa increases dopamine neurotransmission at both D1 and D2 dopamine receptors. Conversely, all the clinically approved dopamine agonists act specifically at the D2/D3 receptor family, with little D1 action. (The one exception is apomorphine, which is a D1 and D2 agonist and which, in its parenteral form, can also be addictive.) Dopamine has long been implicated in reinforcement learning, notably via actions on the basal ganglia. In the striatum, D1 and D2 receptor systems are segregated, the D1 receptor being expressed on neurons of the direct pathway and the D2 on neurons of the indirect pathways 10. Converging evidence from animal experiments 11, computational modeling 12, genetics 13 and cellular biology 14 suggests that D1 receptor stimulation in the direct pathway directly promotes reinforcement learning, while dopamine acting on D2 receptors in the indirect pathway prevents inhibitory or negative learning. Dopamine, therefore, is reinforcing both by activating the direct Go pathway and inhibiting the indirect No-Go pathway. Thus, a drug acting at both D1 and D2 receptors (such as levodopa) would be reinforcing, while a drug acting only at the D2 receptor would prevent negative learning without being very (or at all) rewarding. Such a drug would then not be reinforcing in itself, but could promote or enhance the effects of other reinforcers. Indeed, the animal literature appears to support this model. While there are unequivocal reports of self-administration of D1 agonists in animals 11, the best evidence is that D2 agonists themselves are not self-administered; rather, it appears that they act to enhance the effects of other conditioned stimuli 15. One conceptualization of impulsivity is that it represents impaired inhibition. Similarly, addiction could be said to result from insensitivity to the negative consequences of drug-taking or reward-seeking. In the case of PD patients receiving dopamine agonists, insensitivity to the costs of reward-seeking could be a consequence of excessive stimulation of the D2 receptor. This is consistent with a considerable amount of human and animal evidence implicating variations in D2 receptor signaling as a cause of impulsivity and a risk factor for drug addiction 16-20. None." @default.
• W1506567021 created "2016-06-24" @default.
• W1506567021 creator A5054295358 @default.
• W1506567021 date "2012-01-17" @default.
• W1506567021 modified "2023-09-27" @default.
• W1506567021 title "ADDICTION AS ABERRANT LEARNING-EVIDENCE FROM PARKINSON'S DISEASE" @default.
• W1506567021 cites W1967777407 @default.
• W1506567021 cites W1971999279 @default.
• W1506567021 cites W1983332126 @default.
• W1506567021 cites W1992615559 @default.
• W1506567021 cites W1997829966 @default.
• W1506567021 cites W2023263512 @default.
• W1506567021 cites W2035890213 @default.
• W1506567021 cites W2060588252 @default.
• W1506567021 cites W2076759530 @default.
• W1506567021 cites W2098445519 @default.
• W1506567021 cites W2099440512 @default.
• W1506567021 cites W2100978582 @default.
• W1506567021 cites W2115622614 @default.
• W1506567021 cites W2117332407 @default.
• W1506567021 cites W2134366865 @default.
• W1506567021 cites W2137448503 @default.
• W1506567021 cites W2141474893 @default.
• W1506567021 cites W2157748177 @default.
• W1506567021 cites W2912273041 @default.
• W1506567021 doi "https://doi.org/10.1111/j.1360-0443.2011.03624.x" @default.
• W1506567021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22248132" @default.
• W1506567021 hasPublicationYear "2012" @default.
• W1506567021 type Work @default.
• W1506567021 sameAs 1506567021 @default.
• W1506567021 citedByCount "3" @default.
• W1506567021 countsByYear W15065670212012 @default.
• W1506567021 countsByYear W15065670212013 @default.
• W1506567021 countsByYear W15065670212020 @default.
• W1506567021 crossrefType "journal-article" @default.
• W1506567021 hasAuthorship W1506567021A5054295358 @default.
• W1506567021 hasConcept C118552586 @default.
• W1506567021 hasConcept C126322002 @default.
• W1506567021 hasConcept C15744967 @default.
• W1506567021 hasConcept C2779088608 @default.
• W1506567021 hasConcept C2779134260 @default.
• W1506567021 hasConcept C2779541405 @default.
• W1506567021 hasConcept C2779734285 @default.
• W1506567021 hasConcept C2780304432 @default.
• W1506567021 hasConcept C2780733359 @default.
• W1506567021 hasConcept C2908647359 @default.
• W1506567021 hasConcept C2993290233 @default.
• W1506567021 hasConcept C40010229 @default.
• W1506567021 hasConcept C48856860 @default.
• W1506567021 hasConcept C558461103 @default.
• W1506567021 hasConcept C70410870 @default.
• W1506567021 hasConcept C71924100 @default.
• W1506567021 hasConcept C99454951 @default.
• W1506567021 hasConceptScore W1506567021C118552586 @default.
• W1506567021 hasConceptScore W1506567021C126322002 @default.
• W1506567021 hasConceptScore W1506567021C15744967 @default.
• W1506567021 hasConceptScore W1506567021C2779088608 @default.
• W1506567021 hasConceptScore W1506567021C2779134260 @default.
• W1506567021 hasConceptScore W1506567021C2779541405 @default.
• W1506567021 hasConceptScore W1506567021C2779734285 @default.
• W1506567021 hasConceptScore W1506567021C2780304432 @default.
• W1506567021 hasConceptScore W1506567021C2780733359 @default.
• W1506567021 hasConceptScore W1506567021C2908647359 @default.
• W1506567021 hasConceptScore W1506567021C2993290233 @default.
• W1506567021 hasConceptScore W1506567021C40010229 @default.
• W1506567021 hasConceptScore W1506567021C48856860 @default.
• W1506567021 hasConceptScore W1506567021C558461103 @default.
• W1506567021 hasConceptScore W1506567021C70410870 @default.
• W1506567021 hasConceptScore W1506567021C71924100 @default.
• W1506567021 hasConceptScore W1506567021C99454951 @default.
• W1506567021 hasIssue "2" @default.
• W1506567021 hasLocation W15065670211 @default.
• W1506567021 hasLocation W15065670212 @default.
• W1506567021 hasOpenAccess W1506567021 @default.
• W1506567021 hasPrimaryLocation W15065670211 @default.
• W1506567021 hasRelatedWork W2045365443 @default.
• W1506567021 hasRelatedWork W2170273705 @default.
• W1506567021 hasRelatedWork W2269901594 @default.
• W1506567021 hasRelatedWork W2405043795 @default.
• W1506567021 hasRelatedWork W2892767813 @default.
• W1506567021 hasRelatedWork W2896432742 @default.
• W1506567021 hasRelatedWork W2948450950 @default.
• W1506567021 hasRelatedWork W3202695633 @default.
• W1506567021 hasRelatedWork W329183168 @default.
• W1506567021 hasRelatedWork W4241036646 @default.
• W1506567021 hasVolume "107" @default.
• W1506567021 isParatext "false" @default.
• W1506567021 isRetracted "false" @default.
• W1506567021 magId "1506567021" @default.
• W1506567021 workType "article" @default.